1.Differential expression of plasma extracellular vesicle miRNAs as biomarkers for distinguishing psoriatic arthritis from psoriasis.
Kexiang YAN ; Jie ZHU ; Mengmeng ZHANG ; Fuxin ZHANG ; Bing WANG ; Ling HAN ; Qiong HUANG ; Yulong TANG ; Yuan LI ; Nikhil YAWALKAR ; Zhenghua ZHANG ; Zhenmin NIU
Chinese Medical Journal 2025;138(2):219-221
2.Pancreas transplantation with distal splenic arteriovenous anastomosis to prevent thrombosis: a report of two cases
Xunan TONG ; Zhenghua WU ; Hua CHEN ; Fanjun ZENG ; Zhenxing WANG
Chinese Journal of Organ Transplantation 2025;46(10):731-733
Venous thrombosis is one of the common and serious complications after pancreas transplantation. The organ transplantation center of Shanxi Bethune hospital innovatively improved the previous surgical method of ligating the splenic artery and splenic vein to perform end-to-end anastomosis between the splenic artery and splenic vein in the tail of the pancreas and retain the effective diameter of the splenic artery of about 2 mm to increase the blood flow of splenic vein to prevent thrombosis. The center has successfully completed 2 cases, and the operation effect is good. Postoperative monitoring of abdominal vascular CT angiography showed that the splenic vein reflux was unobstructed. This operation can effectively increase the blood flow of splenic vein and reduce the risk of thrombosis.
3.BK virus nephropathy after allogeneic hematopoietic stem cell transplantation: a case report and literature review
Wenli ZHANG ; Yingling ZU ; Zhenghua HUANG ; Zhen LI ; Ruirui GUI ; Juan WANG ; Xianjing WANG ; Huili WANG ; Xinxin FAN ; Yongping SONG ; Baijun FANG ; Jian ZHOU
Chinese Journal of Hematology 2025;46(3):273-275
A 20-year-old male patient with T-lymphoblastic lymphoma/leukemia received 9/10 human leukocyte antigen-compatible unrelated peripheral blood stem cell transplantation. He was transplanted with 5.91×10 8 mononuclear cells/kg and 2.88×10 6 CD34 + cells/kg, and neutrophil engraftment was obtained at +11 days and platelet engraftment at +9 days. After transplantation, he presented with repeatedly increased serum creatinine levels, BK virus (BKV) -associated hemorrhagic cystitis, and BKV viremia. BK virus nephropathy was diagnosed based on renal biopsy and metagenomic next-generation sequencing. After adjusting the immunosuppressant, intravenous immunoglobulin, and donor lymphocyte infusion treatment, the patient’s renal function deteriorated progressively, and he eventually died of multiple organ failure at +289 days.
4.Minimally invasive therapy for new-onset or residual aortic arch pathology after ascending aortic replacement
Yi XIE ; Peng YANG ; Hongwei ZHANG ; Chen LU ; Yu LIU ; Yu ZHANG ; Qianlei LANG ; Wenfan LI ; Zhenyuan XU ; Chenhao WANG ; Zhenghua XIAO ; Jia HU
Chinese Journal of Thoracic and Cardiovascular Surgery 2025;41(6):366-371
Objective:To evaluate the outcomes of minimally invasive therapy for aortic arch pathology after ascending aortic replacement.Methods:A retrospective analysis was conducted at the Department of Cardiovascular Surgery, West China Hospital of Sichuan University from 2016 to 2024. After multidisciplinary discussion, these included patients were evaluated to be at high risk for traditional open surgery. Various minimally invasive repair techniques were employed, including Ⅳb hybrid technique, physician-modified endograft and novel unibody endograft. The study outcomes were technical success, in-hospital and follow-up mortality, stroke, endoleak, and the patency of the supra-aortic vessels.Results:A total of 40 patients(32 males and 8 females) with a median age of 60 years old were included in this study. The technique success rate was 100%, with no deaths or strokes reported. The patency of the supra-aortic vessels was 100%. 10 patients underwent Type Ⅳb hybrid surgery without any endoleaks occurring. Among the 22 patients who received physician-modified endograft, endoleaks were observed in 2 cases. One of these type Ⅰc endoleaks persisted and underwent reintervention. One patient underwent femoral artery replacement due to vascular injury. For the 8 patients who received novel unibody endograft, one case required reintervention due to persistent type Ⅰc endoleaks.Conclusion:With the development of different endovascular techniques and novel branched endograft, patients with aortic arch pathology who are at high risk for redo open surgery can achieve favorable outcomes with various minimal invasive techniques. However, long-term and large-sample follow-up studies are needed for further evaluation.
5.Clinical Efficacy of Qingchi San for Mild-to-Moderate Active Ulcerative Colitis:A Retrospective Cohort Study
Zhenghua ZHOU ; Fanfan QU ; Jianbin JI ; Hongchang KANG ; Chunyan WANG ; Hui ZHANG
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(10):1282-1287
OBJECTIVE To retrospectively analyze the clinical efficacy of Qingchi San in the treatment of mild-to-moderate ul-cerative colitis.METHODS A retrospective analysis was conducted on 221 ulcerative colitis patients treated at the Gastroenterology Department of First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from December 2014 to February 2024.Participants were divided into an observation group(n=121)and a control group(n=100).The control group received oral me-salazine,while the observation group received Qingchi San enema in addition to the control group's treatment.Both groups received a 4-week course of treatment.The two groups were compared in terms of clinical efficacy,clinical remission rate,TCM syndrome score,time to intestinal bleeding remission,and changes in inflammatory markers(C-reactive protein,erythrocyte sedimentation rate,and white blood cells)and coagulation markers(platelets and D-dimer).RESULTS After treatment,the total effective rate and clinical remission rate in the observation group were significantly higher than those in the control group(P<0.05,P<0.01).The TCM syn-drome scores for each item(diarrhea,abdominal pain,bloody stools with mucus,and tenesmus)in the observation group were signifi-cantly improved compared with those in the control group(P<0.01).The time to intestinal bleeding remission in the observation group was significantly shorter than that in the control group(P<0.01).C-reactive protein,erythrocyte sedimentation rate,and white blood cell count in the observation group were significantly decreased compared with those in the control group(P<0.05,P<0.01).There was no statistically significant difference in coagulation markers(platelets and D-dimer)between the two groups(P>0.05).No signif-icant treatment-related adverse reactions,such as liver and kidney damage,were observed during treatment.CONCLUSION Qing-chi San enema can improve the clinical efficacy of patients with mild-to-moderate ulcerative colitis,improve clinical symptoms,short-en bleeding time,and reduce inflammatory markers.
6.Clinical Efficacy of Qingchi San for Mild-to-Moderate Active Ulcerative Colitis:A Retrospective Cohort Study
Zhenghua ZHOU ; Fanfan QU ; Jianbin JI ; Hongchang KANG ; Chunyan WANG ; Hui ZHANG
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(10):1282-1287
OBJECTIVE To retrospectively analyze the clinical efficacy of Qingchi San in the treatment of mild-to-moderate ul-cerative colitis.METHODS A retrospective analysis was conducted on 221 ulcerative colitis patients treated at the Gastroenterology Department of First Teaching Hospital of Tianjin University of Traditional Chinese Medicine from December 2014 to February 2024.Participants were divided into an observation group(n=121)and a control group(n=100).The control group received oral me-salazine,while the observation group received Qingchi San enema in addition to the control group's treatment.Both groups received a 4-week course of treatment.The two groups were compared in terms of clinical efficacy,clinical remission rate,TCM syndrome score,time to intestinal bleeding remission,and changes in inflammatory markers(C-reactive protein,erythrocyte sedimentation rate,and white blood cells)and coagulation markers(platelets and D-dimer).RESULTS After treatment,the total effective rate and clinical remission rate in the observation group were significantly higher than those in the control group(P<0.05,P<0.01).The TCM syn-drome scores for each item(diarrhea,abdominal pain,bloody stools with mucus,and tenesmus)in the observation group were signifi-cantly improved compared with those in the control group(P<0.01).The time to intestinal bleeding remission in the observation group was significantly shorter than that in the control group(P<0.01).C-reactive protein,erythrocyte sedimentation rate,and white blood cell count in the observation group were significantly decreased compared with those in the control group(P<0.05,P<0.01).There was no statistically significant difference in coagulation markers(platelets and D-dimer)between the two groups(P>0.05).No signif-icant treatment-related adverse reactions,such as liver and kidney damage,were observed during treatment.CONCLUSION Qing-chi San enema can improve the clinical efficacy of patients with mild-to-moderate ulcerative colitis,improve clinical symptoms,short-en bleeding time,and reduce inflammatory markers.
7.BK virus nephropathy after allogeneic hematopoietic stem cell transplantation: a case report and literature review
Wenli ZHANG ; Yingling ZU ; Zhenghua HUANG ; Zhen LI ; Ruirui GUI ; Juan WANG ; Xianjing WANG ; Huili WANG ; Xinxin FAN ; Yongping SONG ; Baijun FANG ; Jian ZHOU
Chinese Journal of Hematology 2025;46(3):273-275
A 20-year-old male patient with T-lymphoblastic lymphoma/leukemia received 9/10 human leukocyte antigen-compatible unrelated peripheral blood stem cell transplantation. He was transplanted with 5.91×10 8 mononuclear cells/kg and 2.88×10 6 CD34 + cells/kg, and neutrophil engraftment was obtained at +11 days and platelet engraftment at +9 days. After transplantation, he presented with repeatedly increased serum creatinine levels, BK virus (BKV) -associated hemorrhagic cystitis, and BKV viremia. BK virus nephropathy was diagnosed based on renal biopsy and metagenomic next-generation sequencing. After adjusting the immunosuppressant, intravenous immunoglobulin, and donor lymphocyte infusion treatment, the patient’s renal function deteriorated progressively, and he eventually died of multiple organ failure at +289 days.
8.Minimally invasive therapy for new-onset or residual aortic arch pathology after ascending aortic replacement
Yi XIE ; Peng YANG ; Hongwei ZHANG ; Chen LU ; Yu LIU ; Yu ZHANG ; Qianlei LANG ; Wenfan LI ; Zhenyuan XU ; Chenhao WANG ; Zhenghua XIAO ; Jia HU
Chinese Journal of Thoracic and Cardiovascular Surgery 2025;41(6):366-371
Objective:To evaluate the outcomes of minimally invasive therapy for aortic arch pathology after ascending aortic replacement.Methods:A retrospective analysis was conducted at the Department of Cardiovascular Surgery, West China Hospital of Sichuan University from 2016 to 2024. After multidisciplinary discussion, these included patients were evaluated to be at high risk for traditional open surgery. Various minimally invasive repair techniques were employed, including Ⅳb hybrid technique, physician-modified endograft and novel unibody endograft. The study outcomes were technical success, in-hospital and follow-up mortality, stroke, endoleak, and the patency of the supra-aortic vessels.Results:A total of 40 patients(32 males and 8 females) with a median age of 60 years old were included in this study. The technique success rate was 100%, with no deaths or strokes reported. The patency of the supra-aortic vessels was 100%. 10 patients underwent Type Ⅳb hybrid surgery without any endoleaks occurring. Among the 22 patients who received physician-modified endograft, endoleaks were observed in 2 cases. One of these type Ⅰc endoleaks persisted and underwent reintervention. One patient underwent femoral artery replacement due to vascular injury. For the 8 patients who received novel unibody endograft, one case required reintervention due to persistent type Ⅰc endoleaks.Conclusion:With the development of different endovascular techniques and novel branched endograft, patients with aortic arch pathology who are at high risk for redo open surgery can achieve favorable outcomes with various minimal invasive techniques. However, long-term and large-sample follow-up studies are needed for further evaluation.
9.Pancreas transplantation with distal splenic arteriovenous anastomosis to prevent thrombosis: a report of two cases
Xunan TONG ; Zhenghua WU ; Hua CHEN ; Fanjun ZENG ; Zhenxing WANG
Chinese Journal of Organ Transplantation 2025;46(10):731-733
Venous thrombosis is one of the common and serious complications after pancreas transplantation. The organ transplantation center of Shanxi Bethune hospital innovatively improved the previous surgical method of ligating the splenic artery and splenic vein to perform end-to-end anastomosis between the splenic artery and splenic vein in the tail of the pancreas and retain the effective diameter of the splenic artery of about 2 mm to increase the blood flow of splenic vein to prevent thrombosis. The center has successfully completed 2 cases, and the operation effect is good. Postoperative monitoring of abdominal vascular CT angiography showed that the splenic vein reflux was unobstructed. This operation can effectively increase the blood flow of splenic vein and reduce the risk of thrombosis.
10.Clinical efficacy of TIPS combined with catheter thrombolysis or local treatment for portal vein thrombosis
Ting CUI ; Tao WANG ; Yu ZHANG ; Dan ZHANG ; Zhendong YUE ; Lei WANG ; Zhenghua FAN ; Yifan WU ; Chengbin DONG ; Fuquan LIU
Journal of Interventional Radiology 2024;33(1):22-27
Objective To investigate the clinical efficacy of transjugular intrahepatic portosystemic shunt(TIPS)combined with indwelling catheter-directed thrombolysis for the treatment of portal vein thrombosis(PVT).Methods The clinical efficacy of 307 patients with portal hypertension complicated by PVT,who received successful TIPS combined with indwelling catheter-directed thrombolysis at the Affiliated Beijing Shijitan Hospital of Capital Medical University of China between January 2016 and December 2019,were retrospectively analyzed.Before and after TIPS,the inferior vena cava pressure(IVCP)and portal vein pressure(PVP)were measured,and the pre-TIPS,post-TIPS(before thrombolysis),and post-thrombolysis portal pressure gradient(PPG,PPG=PVP-IVCP)was separately calculated.Reexamination of portal venography DSA was performed to determine the degree of PVT disappearance and whether the shunt was unobstructed.All patients were followed up for one year.Results The pre-TIPS,post-TIPS(before thrombolysis),and post-thrombolysis mean PPG was(24.50±6.91)mmHg,(18.51±5.11)mmHg,and(10.17±3.97)mmHg,respectively.The post-thrombolysis mean PPG was strikingly lower than the pre-thrombolysis values,the differences were statistically significant(P<0.001).Among the 307 patients,complete disappearance of PVT was observed in 221(72.3%),remarkable reduction of PVT in 86(27.7%),and no invalid result was seen.The patients having complete patency of the shunt flow accounted for 85.7%of the 307 patients(261/307),and the patients having partial patency of the shunt flow accounted for 14.3%of the 307 patients(46/307).Forty-two patients developed complications,and no death occurred.All patients were followed up for one year,and the main clinical symptoms were improved or completely disappeared.Among the 307 patients,an increase in thrombus volume was found in 17(5.5%)when compared to their postoperative values,which returned to the first-time postoperative level after local treatment of the thrombus via the TIPS shunt combined with catheter-directed thrombolysis.Within one year after TIPS and thrombolysis,overt hepatic encephalopathy(OHE)occurred in 54 patients(17.6%,54/307).One patient died of hepatic failure 9 months after TIPS,another patient died of cerebral hemorrhage 11 months after TIPS,and all the remaining patients were alive.Conclusion For patients with portal hypertension complicated by PVT,TIPS combined with indwelling catheter-directed thrombolysis is clinically safe and effective.The standardized,systematic management of the whole therapeutic process should be strengthened.(J Intervent Radiol,2024,32:22-27)

Result Analysis
Print
Save
E-mail